Melanoma screening and public education for minority populations in the United States

The United States Preventive Services Task Force concluded that there is insufficient evidence for clinician skin cancer screening. 1 Force USPST Mangione C.M. Barry M.J. et al. Screening for skin cancer: US preventive Services Task Force recommendation statement. JAMA. 2023; 329: 1290-1295https://doi.org/10.1001/jama.2023.4342 Crossref Scopus (9) Google Scholar Conclusive evidence is not forthcoming, as analyses with power calculations questions the feasibility of a randomized melanoma screening trial. 2 Halvorsen J.A. Loberg M. Gjersvik P. et al. Why a randomized melanoma screening trial is not a good idea. Br J Dermatol. 2018; 179: 532-533https://doi.org/10.1111/bjd.16784 Crossref Scopus (9) Google Scholar It is increasingly recognized that melanoma overdiagnosis requires our attention. 3 Kurtansky N.R. Dusza S.W. Halpern A.C. et al. An epidemiologic analysis of melanoma overdiagnosis in the United States, 1975-2017. J Invest Dermatol. 2022; 142: 1804-1811.e6https://doi.org/10.1016/j.jid.2021.12.003 Abstract Full Text Full Text PDF PubMed Scopus (17) Google Scholar Separately, high melanoma mortality-to-incidence ratios for minority groups have garnered increased attention.